<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1012467</article-id><article-id pub-id-type="publisher-id">ACM-39346</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201200000_94063206.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  产前糖皮质激素使用情况对&lt;34周早产儿预后的影响
  Effect of Antenatal Corticosteroids Use on Prognosis of Preterm Infants &lt; 34 Weeks
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>倩薇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>冉</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>黛婧</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>孙</surname><given-names>启斌</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>单</surname><given-names>若冰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属青岛妇女儿童院NICU，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>07</day><month>12</month><year>2020</year></pub-date><volume>10</volume><issue>12</issue><fpage>3123</fpage><lpage>3130</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：探讨&lt;34周早产儿产前糖皮质激素使用情况对其预后的影响，为临床规范使用产前糖皮质激素提供参考依据。方法：收集2019年1月~2020年6月在青岛妇女儿童医院产科出生收入本院NICU胎龄 &lt; 34周的早产儿的临床资料。所有病例产前使用的糖皮质激素均为地塞米松，根据其使用情况，分为未使用组，使用1~2次组，使用3~4次组。通过检验或秩和检验对比较产前糖皮质激素使用情况对其并发症发生率的影响。结果：研究期间共纳入261例，未使用组共43例(16.48%)，使用1~2次组共66例(25.29%)，使用3~4次组共152例(58.24%)，糖皮质激素使用率83.52%。早产儿一般情况中，使用3~4次组患儿剖宫产发生率和5 min Apgar评分均低于未使用组(P &lt; 0.0167)，在并发症方面，使用组NRDS发生率低于未使用组，并且ACS的使用次数越多，NRDS发生率越低，差异有统计学意义(P &lt; 0.0167)。使用组有创通气 ≥ 7 d的发生率低于未使用组，最高吸入氧浓度也随使用次数增加，逐渐降低。使用3~4次组患儿PDA发生率低于使用1~2次组，使用3~4次组患儿PVL发生率低于未使用组，使用3~4次组患儿纠正6月龄时MDI高于未使用组(P值均 &lt; 0.0167)。结论：产前糖皮质激素在一定程度上能改善早产儿的预后，并且这种改善程度与产前糖皮质激素使用次数有关。
    Objective: To explore the effect of antenatal corticosteroids use in preterm infants &lt; 34 weeks on its prognosis, and to provide a reference for the clinical standard use of prenatal glucocorticoids. Methods: The clinical data of premature infants whose NICU gestational age is less than 34 weeks in Qingdao Women and Children’s Hospital from January 2019 to June 2020 were collected. The corticosteroids used before delivery in all cases was dexamethasone. According to its use, they were divided into non-use group, 1 - 2 times group, and 3 - 4 times group. The incidences of complications were compared between different groups using Chi-square test or rank sum test. Results: A total of 261 cases were enrolled .There were 43 cases (16.48%) in the non-use group, 66 cases (25.29%) in the 1 - 2 times group, and 152 cases (58.24%) in the 3 - 4 times group. The glucocorticoid use rate was 83.52%. In the general situation of preterm infants, the incidence of cesarean section and 5 min Apgar score of children in the 3 - 4 times group were lower than those in the non-use group (P &lt; 0.0167). In terms of complications, the incidence of NRDS in the ACS group was lower than that in the non-use group. In addition, the incidence of invasive ventilation greater than or equal to 7 days in the ACS use group was lower than that in the non-use group, and the maximum inhaled oxygen concentration also increased with the use of ACS, and gradually decreased. The incidence of PDA in the 3 - 4 times of use group was lower than that in the 1~2 times of use group, the incidence of PVL in the 3 - 4 times of use group was lower than that in the no-use group, and MDI corrected at 6 months of age in the 3 - 4 times of use group was higher than that in the no-use group (P &lt; 0.0167). Conclusions: Antenatal corticosteroids can improve the prognosis of preterm infants to a certain extent, and the degree of improvement is related to the frequency of antenatal corticosteroids use. 
  
 
</p></abstract><kwd-group><kwd>糖皮质激素，婴儿，早产，并发症，预后, Glucocorticoids</kwd><kwd> Infant</kwd><kwd> Premature</kwd><kwd> Complications</kwd><kwd> Prognosis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：探讨&lt;34周早产儿产前糖皮质激素使用情况对其预后的影响，为临床规范使用产前糖皮质激素提供参考依据。方法：收集2019年1月~2020年6月在青岛妇女儿童医院产科出生收入本院NICU胎龄 &lt; 34周的早产儿的临床资料。所有病例产前使用的糖皮质激素均为地塞米松，根据其使用情况，分为未使用组，使用1~2次组，使用3~4次组。通过c<sup>2</sup>检验或秩和检验对比较产前糖皮质激素使用情况对其并发症发生率的影响。结果：研究期间共纳入261例，未使用组共43例(16.48%)，使用1~2次组共66例(25.29%)，使用3~4次组共152例(58.24%)，糖皮质激素使用率83.52%。早产儿一般情况中，使用3~4次组患儿剖宫产发生率和5 min Apgar评分均低于未使用组(P &lt; 0.0167)，在并发症方面，使用组NRDS发生率低于未使用组，并且ACS的使用次数越多，NRDS发生率越低，差异有统计学意义(P &lt; 0.0167)。使用组有创通气 ≥ 7 d的发生率低于未使用组，最高吸入氧浓度也随使用次数增加，逐渐降低。使用3~4次组患儿PDA发生率低于使用1~2次组，使用3~4次组患儿PVL发生率低于未使用组，使用3~4次组患儿纠正6月龄时MDI高于未使用组(P值均 &lt; 0.0167)。结论：产前糖皮质激素在一定程度上能改善早产儿的预后，并且这种改善程度与产前糖皮质激素使用次数有关。</p></sec><sec id="s2"><title>关键词</title><p>糖皮质激素，婴儿，早产，并发症，预后</p></sec><sec id="s3"><title>Effect of Antenatal Corticosteroids Use on Prognosis of Preterm Infants &lt; 34 Weeks<sup> </sup></title><p>Qianwei Zhang, Ran Ding, Daijing Wang, Qibin Sun, Ruobing Shan<sup>*</sup></p><p>Department of NICU, Qingdao Women and Children’s Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/37-1571792x5_hanspub.png" /></p><p>Received: Nov. 21<sup>st</sup>, 2020; accepted: Dec. 17<sup>th</sup>, 2020; published: Dec. 24<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/37-1571792x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To explore the effect of antenatal corticosteroids use in preterm infants &lt; 34 weeks on its prognosis, and to provide a reference for the clinical standard use of prenatal glucocorticoids. Methods: The clinical data of premature infants whose NICU gestational age is less than 34 weeks in Qingdao Women and Children’s Hospital from January 2019 to June 2020 were collected. The corticosteroids used before delivery in all cases was dexamethasone. According to its use, they were divided into non-use group, 1 - 2 times group, and 3 - 4 times group. The incidences of complications were compared between different groups using Chi-square test or rank sum test. Results: A total of 261 cases were enrolled .There were 43 cases (16.48%) in the non-use group, 66 cases (25.29%) in the 1 - 2 times group, and 152 cases (58.24%) in the 3 - 4 times group. The glucocorticoid use rate was 83.52%. In the general situation of preterm infants, the incidence of cesarean section and 5 min Apgar score of children in the 3 - 4 times group were lower than those in the non-use group (P &lt; 0.0167). In terms of complications, the incidence of NRDS in the ACS group was lower than that in the non-use group. In addition, the incidence of invasive ventilation greater than or equal to 7 days in the ACS use group was lower than that in the non-use group, and the maximum inhaled oxygen concentration also increased with the use of ACS, and gradually decreased. The incidence of PDA in the 3 - 4 times of use group was lower than that in the 1~2 times of use group, the incidence of PVL in the 3 - 4 times of use group was lower than that in the no-use group, and MDI corrected at 6 months of age in the 3 - 4 times of use group was higher than that in the no-use group (P &lt; 0.0167). Conclusions: Antenatal corticosteroids can improve the prognosis of preterm infants to a certain extent, and the degree of improvement is related to the frequency of antenatal corticosteroids use.</p><p>Keywords:Glucocorticoids, Infant, Premature, Complications, Prognosis</p><disp-formula id="hanspub.39346-formula15"><graphic xlink:href="//html.hanspub.org/file/37-1571792x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/37-1571792x8_hanspub.png" /> <img src="//html.hanspub.org/file/37-1571792x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>随着高危孕产妇产前诊疗技术和危重早产儿救治能力的不断提升，我国早产儿存活率不断提高，2019年报告显示，全球早产儿发生率为10.6% (9.0%~12.0%)，中国早产儿发生率为6.9% (5.8~7.9%) [<xref ref-type="bibr" rid="hanspub.39346-ref1">1</xref>]。早产是导致围生儿并发症和死亡的主要原因，肺部发育不成熟直接影响早产儿的预后。产前糖皮质激素(antenatal corticosteroids, ACS)应用是促进胎肺成熟，改善早产儿预后的重要产前干预措施，是早产儿存活的独立危险因素 [<xref ref-type="bibr" rid="hanspub.39346-ref2">2</xref>]。2019年欧洲新生儿呼吸窘迫综合征防治指南更加强调对妊娠34周内存在早产儿风险的孕妇至少在分娩前24 h给予单疗程产前糖皮质激素治疗 [<xref ref-type="bibr" rid="hanspub.39346-ref3">3</xref>]。本研究观察ACS使用情况对&lt;34周早产儿并发症的影响，为临床更加积极规范使用ACS提供诊疗依据。</p></sec><sec id="s6"><title>2. 资料与方法</title><sec id="s6_1"><title>2.1. 研究对象</title><p>收集2019年1月~2020年6月在青岛妇女儿童医院产科出生收入本院NICU胎龄 &lt; 34周的早产儿的临床资料。根据ACS使用情况，分为未使用组，使用1~2次组，使用3~4次组。入选标准：1) 在我院产科出生并收入我院NICU住院，其胎龄 &lt; 34周的早产儿，孕母均进行胎盘病理检查；2) 患者家属知情同意并积极治疗，病例资料完整。排除标准：1) 早产儿存在致死性先天畸形(如中枢神经系统畸形等)，膈疝，呼吸系统畸形，除室间隔缺损、房间隔缺损或动脉导管未闭外的严重先天性心脏病；2) 遗传代谢病及染色体病；3) 住院期间中途放弃治疗或病例资料不完整。本研究已通过伦理审查(意见编号：QFELL-YJ-2020-40)。</p></sec><sec id="s6_2"><title>2.2. 诊断方法</title><p>产前糖皮质激素使用情况参照我国2014年发布的“早产临床诊断与治疗指南”，分娩7天内使用地塞米松6 mg肌肉注射(每12小重复1次，共4次)为一个完整疗程 [<xref ref-type="bibr" rid="hanspub.39346-ref4">4</xref>]。</p><p>并发症的诊断标准：新生儿呼吸窘迫综合征(neonatalrespiratory distress syndrome, NRDS)、支气管肺发育不良(bronchopulmonary dysplasia, BPD)、败血症、坏死性小肠结肠炎(necrotizing enterocolitis, NEC)、早产儿视网膜病变(retinopathy of prematurity, ROP)、动脉导管未闭(patentductus arteriosus, PDA)、肺出血、脑室周围白质软化(patent ductus arteriosus, PVL)等标准参照第4版《实用新生儿学》 [<xref ref-type="bibr" rid="hanspub.39346-ref5">5</xref>]，组织学绒毛膜羊膜炎参照《妇产科病理诊断学》 [<xref ref-type="bibr" rid="hanspub.39346-ref6">6</xref>]，胎膜早破、胎膜早剥诊断参照第8版《妇产科学》 [<xref ref-type="bibr" rid="hanspub.39346-ref7">7</xref>]。</p></sec><sec id="s6_3"><title>2.3. 研究方法</title><p>所收集资料：1) 早产儿一般情况：胎龄、性别、出生体重、生产方式、宫内窘迫史、窒息史、5 min Apgar评分、危重症情况、新生儿肺炎、败血症、PDA；2) 早产儿呼吸情况：呼吸窘迫评分、使用PS、咖啡因情况、机械通气时间、最高吸入FiO<sub>2</sub>、无创通气时间、总呼吸支持时间；3) 早产儿纠正6月龄和12月龄贝利测试结果。4) 孕母资料：年龄、胎膜早破史、HCA、胎盘早剥史、妊娠期高血压疾病、妊娠期糖尿病及ACS使用情况。</p></sec><sec id="s6_4"><title>2.4. 统计学方法</title><p>应用SPSS 21.0统计软件进行数据分析。正态分布的计量资料以均数 &#177; 标准差( x &#175; &#177; s)表示，组间比较采用单因素方差分析；非正态分布的计量资料以中位数和四分位数间距[M (Q1, Q3)]表示，组间比较采用秩和检验；计数资料采用例数和百分比[n (%)]，组间比较采用c<sup>2</sup>检验或校正c<sup>2</sup>检验。组间比较P &lt; 0.05差异有统计学意义，组间两两比较P &lt; 0.0167差异有统计学意义。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 一般资料</title><p>研究期间共收治胎龄 &lt; 34周单胎早产儿共349例，排除严重发育畸形，遗传代谢疾病，中途放弃治疗，资料不全等58例，共纳入261例，男婴161例，女婴100例。其中胎龄为(31.56 &#177; 1.86)周，范围为27 + 1~33 + 6周；出生体重为(1720.48 &#177; 407.86) g，范围为890~2860 g。根据ACS使用情况，未使用组共43例(16.48%)，使用1~2次组共66例(25.29%)，使用3~4次组共152例(58.24%)，ACS使用率83.52%。</p></sec><sec id="s7_2"><title>3.2. 3组早产儿及孕母一般情况比较</title><sec id="s7_2_1"><title>3.2.1. 新生儿因素</title><p>使用3~4次组患儿剖宫产发生率和5 min Apgar评分均低于未使用组，而使用组HCA发生率高于未使用组(P值均 &lt; 0.0167)。见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the general conditions of the 3 groups of premature infant</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >胎龄(M (Q1, Q3)，周)</th><th align="center" valign="middle" >出生体重( x &#175; &#177; s, g)</th><th align="center" valign="middle" >男婴(例，%)</th><th align="center" valign="middle" >剖宫产 (例，%)</th><th align="center" valign="middle" >血糖(M (Q1, Q3), mmol/L)</th></tr></thead><tr><td align="center" valign="middle" >未使用组</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >32.43 (31.14, 33.56)</td><td align="center" valign="middle" >1754.02 &#177; 381.84</td><td align="center" valign="middle" >2 (62.8%)</td><td align="center" valign="middle" >31 (72.1%)</td><td align="center" valign="middle" >3.7 (3.0, 4.37)</td></tr><tr><td align="center" valign="middle" >使用1~2次组</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >32.56 (29.86, 33.71)</td><td align="center" valign="middle" >1757.27 &#177; 436.31</td><td align="center" valign="middle" >43 (65.2%)</td><td align="center" valign="middle" >31 (47.0%)</td><td align="center" valign="middle" >3.7 (3.28, 4.15)</td></tr><tr><td align="center" valign="middle" >使用3~4次组</td><td align="center" valign="middle" >152</td><td align="center" valign="middle" >31.71 (30, 33.56)</td><td align="center" valign="middle" >1695.01 &#177; 402.95</td><td align="center" valign="middle" >91 (59.9%)</td><td align="center" valign="middle" >78 (51.3%)<sup>a</sup></td><td align="center" valign="middle" >3.7 (3.1, 4.3)</td></tr><tr><td align="center" valign="middle" >H、F或c<sup>2</sup>值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.921</td><td align="center" valign="middle" >0.709</td><td align="center" valign="middle" >0.752</td><td align="center" valign="middle" >7.399</td><td align="center" valign="middle" >4.184</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.085</td><td align="center" valign="middle" >0.493</td><td align="center" valign="middle" >0.587</td><td align="center" valign="middle" >0.025</td><td align="center" valign="middle" >0.123</td></tr></tbody></table></table-wrap><p>表1. 3组早产儿一般情况比较</p><p>注：a为与未使用组比较，p &lt; 0.0167；b为与未使用组比较，p &lt; 0.0167；c为与未使用组比较，p &lt; 0.167；d为与未使用组比较，p &lt; 0.167；HCA：组织学绒毛膜羊膜炎。</p></sec><sec id="s7_2_2"><title>3.2.2. 母亲因素</title><p>使用3~4次组患儿孕母胎膜早破发生率高于未使用组，而胎盘早剥发生率低于未使用组(P值均 &lt; 0.0167)。见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the general situation of three groups of pregnant wome</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >年龄( x &#175; &#177; s，年)</th><th align="center" valign="middle" >妊娠期糖尿病(例，%)</th><th align="center" valign="middle" >妊娠期高血压(例，%)</th><th align="center" valign="middle" >胎膜早破 (例，%)</th><th align="center" valign="middle" >胎盘早剥 (例，%)</th></tr></thead><tr><td align="center" valign="middle" >未使用组</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >31.48 &#177; 4.83</td><td align="center" valign="middle" >15 (34.9%)</td><td align="center" valign="middle" >4 (9.3%)</td><td align="center" valign="middle" >17 (39.5%)</td><td align="center" valign="middle" >9 (20.9%)</td></tr><tr><td align="center" valign="middle" >使用1~2次组</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >32.38 &#177; 5.23</td><td align="center" valign="middle" >20 (30.3%)</td><td align="center" valign="middle" >2 (3%)</td><td align="center" valign="middle" >34 (51.5%)</td><td align="center" valign="middle" >14 (21.2%)</td></tr><tr><td align="center" valign="middle" >使用3~4次组</td><td align="center" valign="middle" >152</td><td align="center" valign="middle" >31.45 &#177; 4.34</td><td align="center" valign="middle" >32 (21.1%)</td><td align="center" valign="middle" >14 (9.2%)</td><td align="center" valign="middle" >95 (62.5%)<sup>e</sup></td><td align="center" valign="middle" >15 (9.9%)<sup>f</sup></td></tr><tr><td align="center" valign="middle" >H、F或c<sup>2</sup>值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.967</td><td align="center" valign="middle" >4.354</td><td align="center" valign="middle" >3.194</td><td align="center" valign="middle" >7.837</td><td align="center" valign="middle" >6.440</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.381</td><td align="center" valign="middle" >0.107</td><td align="center" valign="middle" >0.209</td><td align="center" valign="middle" >0.020</td><td align="center" valign="middle" >0.042</td></tr></tbody></table></table-wrap><p>表2. 3组孕母一般情况比较</p><p>注：e为与未使用组比较，p &lt; 0.167；f为与未使用组比较，p &lt; 0.167。</p></sec></sec><sec id="s7_3"><title>3.3. 产前糖皮质激素使用情况</title><p>本研究所收集的资料显示，随着出生胎龄或体重的增加，产前地塞米松的使用率变化趋势不明显，(P值均 &gt; 0.05)见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Influence of gestational age and weight on prenatal glucocorticoid us</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >因素</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >未使用组</th><th align="center" valign="middle" >使用1~2次组</th><th align="center" valign="middle" >使用3~4次组</th><th align="center" valign="middle" >统计值</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >胎龄(周)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >6.768</td><td align="center" valign="middle" >0.343<sup>g</sup></td></tr><tr><td align="center" valign="middle" >&lt;28</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >1 (10%)</td><td align="center" valign="middle" >5 (50%)</td><td align="center" valign="middle" >4 (40%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥28~&lt;30</td><td align="center" valign="middle" >50</td><td align="center" valign="middle" >7 (14%)</td><td align="center" valign="middle" >11 (22%)</td><td align="center" valign="middle" >32 (64%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥30~&lt;32</td><td align="center" valign="middle" >65</td><td align="center" valign="middle" >8 (12.3%)</td><td align="center" valign="middle" >14 (21.5%)</td><td align="center" valign="middle" >43 (66.2%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥32~&lt;34</td><td align="center" valign="middle" >136</td><td align="center" valign="middle" >27 (19.9%)</td><td align="center" valign="middle" >36 (26.5%)</td><td align="center" valign="middle" >73 (53.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >出生体重(g)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2.11</td><td align="center" valign="middle" >0.928<sup>g</sup></td></tr><tr><td align="center" valign="middle" >&lt;1000</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >1 (11.1%)</td><td align="center" valign="middle" >2 (22.2%)</td><td align="center" valign="middle" >6 (66.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥1000~&lt;1500</td><td align="center" valign="middle" >62</td><td align="center" valign="middle" >11 (17.7%)</td><td align="center" valign="middle" >13 (21%)</td><td align="center" valign="middle" >38 (61.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥1500~&lt;2500</td><td align="center" valign="middle" >181</td><td align="center" valign="middle" >29 (16%)</td><td align="center" valign="middle" >48 (26.5%)</td><td align="center" valign="middle" >104 (57.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >≥1500</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >2 (22.2%)</td><td align="center" valign="middle" >3 (33.3%)</td><td align="center" valign="middle" >4 (44.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr></tbody></table></table-wrap><p>表3. 胎龄和体重对产前糖皮质激素使用情况的影响</p><p>注：g趋势c<sup>2</sup>检验。</p></sec><sec id="s7_4"><title>3.4. 产前糖皮质激素使用情况对3组早产儿呼吸系统干预的影响</title><p>使用3~4次组有创通气 ≥ 7 d的发生率低于未使用组，使用3~4次组最高吸入氧浓度FiO<sub>2</sub> ≥ 50%发生率低于使用1~2次组(P值均 &lt; 0.0167)见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Respiratory intervention of premature infants in the 3 group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >呼吸窘迫评分(M (Q1, Q3))</th><th align="center" valign="middle" >使用PS (例，%)</th><th align="center" valign="middle" >有创通气 ≥ 7 d (例，%)</th><th align="center" valign="middle" >最高吸入氧浓度FiO<sub>2</sub> ≥ 50% (例，%)</th><th align="center" valign="middle" >总呼吸支持时间(M (Q1, Q3))</th></tr></thead><tr><td align="center" valign="middle" >未使用组</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >3 (1, 7)</td><td align="center" valign="middle" >10 (23.3%)</td><td align="center" valign="middle" >8 (18.6)</td><td align="center" valign="middle" >5 (11.6%)</td><td align="center" valign="middle" >3 (0, 10.5)</td></tr><tr><td align="center" valign="middle" >使用1~2次组</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >3 (2, 6)</td><td align="center" valign="middle" >10 (15.2%)</td><td align="center" valign="middle" >8 (12.1%)</td><td align="center" valign="middle" >10 (15.2%)</td><td align="center" valign="middle" >6 (0, 22.25)</td></tr><tr><td align="center" valign="middle" >使用3~4次组</td><td align="center" valign="middle" >152</td><td align="center" valign="middle" >3 (1, 5)</td><td align="center" valign="middle" >24 (15.8%)</td><td align="center" valign="middle" >6 (3.9%)<sup>h</sup></td><td align="center" valign="middle" >8 (5.3%)<sup>i</sup></td><td align="center" valign="middle" >3 (0, 22)</td></tr><tr><td align="center" valign="middle" >H、F或c<sup>2</sup>值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.188</td><td align="center" valign="middle" >1.517</td><td align="center" valign="middle" >10.309</td><td align="center" valign="middle" >6.107</td><td align="center" valign="middle" >0.826</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.123</td><td align="center" valign="middle" >0.475</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >0.047</td><td align="center" valign="middle" >0.662</td></tr></tbody></table></table-wrap><p>表4. 3组早产儿呼吸系统干预情况</p><p>注：h为未使用组比较，P &lt; 0.167；i为与使用1~2次组比较，P &lt; 0.0167；PS：肺表面活性物质。</p></sec><sec id="s7_5"><title>3.5. 产前糖皮质激素使用情况对3组早产儿并发症发生率的影响</title><p>使用3~4次组患儿NRDS发生率均低于使用1~2次组及未使用组；使用3~4次组患儿PDA发生率低于使用1~2次组；使用3~4次组患儿PVL发生率低于未使用组，(P值均 &lt; 0.0167)见表5。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Influence of prenatal glucocorticoid use on the incidence of complications in three groups of premature infant</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >NRDS (例，%)</th><th align="center" valign="middle" >呼吸衰竭(例，%)</th><th align="center" valign="middle" >肺出血(例，%)</th><th align="center" valign="middle" >PPHN (例，%)</th><th align="center" valign="middle" >BPD (例，%)</th></tr></thead><tr><td align="center" valign="middle" >未使用组</td><td align="center" valign="middle" >43</td><td align="center" valign="middle" >16 (37.2%)</td><td align="center" valign="middle" >10 (23.3%)</td><td align="center" valign="middle" >0 (0%)</td><td align="center" valign="middle" >2 (4.7%)</td><td align="center" valign="middle" >7 (16.7%)</td></tr><tr><td align="center" valign="middle" >使用1~2次组</td><td align="center" valign="middle" >66</td><td align="center" valign="middle" >24 (36.4%)<sup>j</sup></td><td align="center" valign="middle" >13 (19.7%)</td><td align="center" valign="middle" >3 (4.5%)</td><td align="center" valign="middle" >4 (6.1%)</td><td align="center" valign="middle" >14 (21.2%)</td></tr><tr><td align="center" valign="middle" >使用3~4次组</td><td align="center" valign="middle" >152</td><td align="center" valign="middle" >24 (15.8%)<sup>k</sup></td><td align="center" valign="middle" >28 (18.4%)</td><td align="center" valign="middle" >1 (0.7%)</td><td align="center" valign="middle" >6 (3.9%)</td><td align="center" valign="middle" >36 (23.7%)</td></tr><tr><td align="center" valign="middle" >H、F或c<sup>2</sup>值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >15.003</td><td align="center" valign="middle" >0.500</td><td align="center" valign="middle" >3.905</td><td align="center" valign="middle" >0.712</td><td align="center" valign="middle" >0.973</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >0.779</td><td align="center" valign="middle" >0.076</td><td align="center" valign="middle" >0.775</td><td align="center" valign="middle" >0.615</td></tr></tbody></table></table-wrap><p>表5. 产前糖皮质激素使用情况对3组早产儿并发症发生率的影响</p><p>注：j为与使用3~4次组比较，P &lt; 0.0167；k为与未使用组比较，P &lt; 0.0167；l为与1~2次组比较，P &lt; 0.0167；m为与未使用组比较，P &lt; 0.0167；NRDS：新生儿呼吸窘迫综合征；PPHN：新生儿持续性肺动脉高压；ROP：早产儿视网膜病；PDA：动脉导管未闭；PVL：脑室周围白质软化。</p></sec><sec id="s7_6"><title>3.6. 产前糖皮质激素使用情况对3组早产儿纠正6月龄和12月龄的神经系统影响</title><p>对纳入研究中的53例早产儿进行了为期1年的随访，使用3~4次患儿纠正6月龄时MDI高于未使用组，(P值 &lt; 0.0167)，见表6。</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Bailey test results of the 3 groups of premature infants corrected at 6 months and 12 month</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >纠正6月龄MDI ( &#177; s)</th><th align="center" valign="middle" >纠正6月龄PDI ( x &#175; &#177; s)</th><th align="center" valign="middle" >纠正12月龄MDI ( &#177; s)</th><th align="center" valign="middle" >纠正12月龄PDI ( x &#175; &#177; s)</th></tr></thead><tr><td align="center" valign="middle" >未使用组</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >97.00 &#177; 4.39</td><td align="center" valign="middle" >101.11 &#177; 8.44</td><td align="center" valign="middle" >104.22 &#177; 12.39</td><td align="center" valign="middle" >112.33 &#177; 11.41</td></tr><tr><td align="center" valign="middle" >使用1~2次组</td><td align="center" valign="middle" >10</td><td align="center" valign="middle" >98.6 &#177; 7.94</td><td align="center" valign="middle" >103.60 &#177; 11.97</td><td align="center" valign="middle" >110.50 &#177; 17.10</td><td align="center" valign="middle" >107.50 &#177; 10.26</td></tr><tr><td align="center" valign="middle" >使用3~4次组</td><td align="center" valign="middle" >34</td><td align="center" valign="middle" >107.24 &#177; 9.77<sup>n</sup></td><td align="center" valign="middle" >103.29 &#177; 8.17</td><td align="center" valign="middle" >112.29 &#177; 11.73</td><td align="center" valign="middle" >115.62 &#177; 10.08</td></tr><tr><td align="center" valign="middle" >H、F或c<sup>2</sup>值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >7.021</td><td align="center" valign="middle" >0.238</td><td align="center" valign="middle" >1.380</td><td align="center" valign="middle" >2.454</td></tr><tr><td align="center" valign="middle" >P值</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.002</td><td align="center" valign="middle" >0.789</td><td align="center" valign="middle" >0.260</td><td align="center" valign="middle" >0.096</td></tr></tbody></table></table-wrap><p>表6. 3组早产儿纠正6月龄和12月龄的贝利测试结果</p><p>注：n为与未使用组比较，P &lt; 0.0167；MDI：智力发展指数；PDI：精神运动发展指数。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>糖皮质激素是一种甾体类化物，具有抗炎、抗过敏、抗休克及免疫抑制等生物学功能。1969年Liggins等在利用孕羊分娩动因时发现暴露于糖皮质激素的胎羊早产生存率显著提高 [<xref ref-type="bibr" rid="hanspub.39346-ref8">8</xref>]。随后，大量的循证医学证据表明产前糖皮质激素可以降低早产儿死亡率、降低NRDS风险，还可以降低早产儿脑室内出血、PVL和NEC的风险 [<xref ref-type="bibr" rid="hanspub.39346-ref9">9</xref>]。2017年我国早产儿NRDS流行病学调查协作组对全国14家综合医院出生的6437例早产儿回顾性的研究发现，胎龄24~31 + 6周组产前使用糖皮质激素的早产儿的死亡率和NRDS的发生率均明显低于未使用糖皮质激素组，胎龄32~34 + 6周组产前使用糖皮质激素的早产儿IVH的发生率明显高于未使用糖皮质激素组 [<xref ref-type="bibr" rid="hanspub.39346-ref10">10</xref>]。</p><p>因新生儿肺成熟程度与孕周密切相关，糖皮质激素可以促进胎肺合成、释放肺表面活性物质，从而降低新生儿呼吸窘迫综合征的发生率。本研究显示，在胎龄 &lt; 34周患儿中ACS使用组NRDS发生率低于未使用组，并且ACS的使用次数越多，NRDS发生率越低，差异有统计学意义(P &lt; 0.0167)。ACS使用组有创通气 ≥ 7 d的发生率低于未使用组，最高吸入氧浓度也随使用ACS的次数增加，逐渐降低。研究表明，糖皮质激素能激活内皮型一氧化氮合酶，提高出生时肺顺应性，增加肺上皮细胞钠离子通道，清除肺内多余液体，改善肺通气/灌注 [<xref ref-type="bibr" rid="hanspub.39346-ref11">11</xref>]。本研究中，ACS使用3~4次组PDA的发生率较1~2次组明显降低，考虑与于上述机制中GC增加肺的顺应性，改善V/Q比值，促进动脉导管平滑肌收缩有关，从而降低PDA的发生率。</p><p>产前糖皮质激素的作用远远大于促胎肺成熟。2017年美国妇产医学会发布的最新意见 [<xref ref-type="bibr" rid="hanspub.39346-ref12">12</xref>]，明确指出在预期早产前应用糖皮质激素是最重要的产前治疗，通过胎盘对胎儿全身多个器官、多系统都有全面的促进作用，而绝非选择性作用于肺部。Meta分析表明，有早产风险的孕妇产前给予1疗程的GC可以降低34周前出生的患儿的脑瘫、精神运动发育指数低于70、严重残疾风险及提高无病生存率 [<xref ref-type="bibr" rid="hanspub.39346-ref13">13</xref>]。本研究中ACS使用3~4次组PVL的发生率低于未使用组，并且纠正6月龄时智力发展指数明显高于未使用组，与国内外研究基本一致 [<xref ref-type="bibr" rid="hanspub.39346-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.39346-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.39346-ref16">16</xref>]。</p><p>国内外已有多个指南或专家共识推荐应用产前糖皮质激素 [<xref ref-type="bibr" rid="hanspub.39346-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.39346-ref17">17</xref>] [<xref ref-type="bibr" rid="hanspub.39346-ref18">18</xref>]，2019年欧洲NRDS防治指南建议，对于34周内存在早产风险的孕妇，均应在分娩前24 h给予单疗程的产前糖皮质激素治疗，如果距离第1个疗程已1~2周，孕周仍小于32周，且有早产征象的孕妇，可以重复给予1个疗程的激素。然而，国内产前糖皮质激素的使用率仍大大落后于发达国家。有报道显示，2014年国内13家协作医院早产儿ACS使用率37.5%，其中&lt;32周早产儿ACS使用率57.3% [<xref ref-type="bibr" rid="hanspub.39346-ref10">10</xref>]。广东省26家三级甲等综合医院对2013年1月1日至2017年12月31日的超未成熟儿及超低出生体重儿前瞻性研究显示，产前糖皮质激素的使用率为53.0%，使用满一个疗程的占30.3%，不满一个疗程的占22.7%，未使用的占47.0% [<xref ref-type="bibr" rid="hanspub.39346-ref16">16</xref>]。而加拿大2015年32周以下患儿ACS使用率为86%，澳大利亚2015年32周以下患儿ACS使用率为90.4% [<xref ref-type="bibr" rid="hanspub.39346-ref19">19</xref>]。本研究34周以下患儿ACS的使用率为83.52%，仍低于国外发达国家水平。</p><p>本研究的局限性：首先，本研究是单中心研究，样本量小，可能会对并发症的发生率计算有出入，有待进行多中心大样本研究；其次，本研究为回顾性研究，3组孕母部分基本情况并不完全一致，不除外对研究结果产生影响；最后，本研究未考虑糖皮质激素对早产儿死亡率的统计。</p></sec><sec id="s9"><title>5. 结论</title><p>综上所述，产前糖皮质激素在一定程度上能降低早产儿NRDS、PDA、PVL的发生率，降低有创通气时间及最高吸入氧浓度，提高早产儿纠正6月龄的智力发展指数，改善早产儿预后。所以，临床医生应该正确认识产前糖皮质激素的有作用，深化“促胎肺成熟”转变为“促胎儿成熟”的治疗观念，更加重视产前糖皮质激素在24~34 + 6周早产儿的使用。</p></sec><sec id="s10"><title>基金项目</title><p>青岛市民生科技计划项目(14-2-3-28-nsh)。</p></sec><sec id="s11"><title>文章引用</title><p>张倩薇,丁 冉,王黛婧,孙启斌,单若冰. 产前糖皮质激素使用情况对&lt;34周早产儿预后的影响Effect of Antenatal Corticosteroids Use on Prognosis of Preterm Infants &lt; 34 Weeks[J]. 临床医学进展, 2020, 10(12): 3123-3130. https://doi.org/10.12677/ACM.2020.1012467</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.39346-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Chawanpaiboon, S., Vogel, J.P., Moller, A.B., et al. (2019) Global, Regional, and National Estimates of Levels of Preterm Birth in 2014: A Systematic Review and Modelling Analysis. The Lancet Global Health, 7, e37-e46.  
&lt;br&gt;https://doi.org/10.1016/S2214-109X(18)30451-0</mixed-citation></ref><ref id="hanspub.39346-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Roberts, D., Brown, J., Medley, N., et al. (2017) Antenatal Corticosteroids for Accelerating Fetal Lung Maturation for Women at Risk of Preterm Birth. Cochrane Database of Systematic Reviews, 3, CD004454.  
&lt;br&gt;https://doi.org/10.1002/14651858.CD004454.pub3</mixed-citation></ref><ref id="hanspub.39346-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Sweet, D.G., Carnielli, V., Greisen, G., et al. (2019) European Consensus Guidelines on the Management of Respiratory Distress Syndrome-2019 Update. Neonatology, 115, 432-450. &lt;br&gt;https://doi.org/10.1159/000499361</mixed-citation></ref><ref id="hanspub.39346-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会妇产科学分会产科学组. 早产临床诊断与治疗指南(2014) [J]. 中华妇产科杂志, 2014, 49(7): 481-485.</mixed-citation></ref><ref id="hanspub.39346-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">邵肖梅, 叶鸿瑁, 丘小汕. 实用新生儿学[M]. 第4版. 北京: 人民卫生出版社, 2011: 416-423.</mixed-citation></ref><ref id="hanspub.39346-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">回允中. 妇产科诊断病理学(精) [M]. 第3版. 北京: 北京大学医学出版社, 2007: 1086-1087.</mixed-citation></ref><ref id="hanspub.39346-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">谢幸, 苟文丽. 妇产科学[M]. 第8版. 北京: 人民卫生出版社, 2013: 58-61.</mixed-citation></ref><ref id="hanspub.39346-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Liggins, G.C. (1967) Premature Delivery of Fetal Lambs Infused with Gluco-Corticoids. Journal of Endocrinology, 45, 515-523. &lt;br&gt;https://doi.org/10.1677/joe.0.0450515</mixed-citation></ref><ref id="hanspub.39346-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Hayes, E.J., Paul, D.A., Stahl, G.E., et al. (2008) Effect of Antenatal Corticosteroids on Survival for Neonates Born at 23 Weeks of Gestation. Obstetrics &amp; Gynecology, 111, 921-926. &lt;br&gt;https://doi.org/10.1097/AOG.0b013e318169ce2d</mixed-citation></ref><ref id="hanspub.39346-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">早产儿呼吸窘迫综合征流行病学调查协作组. 产前糖皮质激素对早产小于胎龄儿病死率和主要并发症的影响[J]. 中华儿科杂志, 2017, 55(8): 613-618.</mixed-citation></ref><ref id="hanspub.39346-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Haviv, H.R., Said, J. and Mol, B.W. (2019) The Place of Antenatal Corticosteroids in Late Preterm and Early Term Births. Seminars in Fetal &amp; Neonatal Medicine, 24, 37-42. &lt;br&gt;https://doi.org/10.1016/j.siny.2018.10.001</mixed-citation></ref><ref id="hanspub.39346-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Committee on Obstetric Practice (2017) ACOG Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstetrics &amp; Gynecology, 130, e102-e109. &lt;br&gt;https://doi.org/10.1097/AOG.0000000000002237</mixed-citation></ref><ref id="hanspub.39346-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Sotiriadis, A., Tsiami, A., Papatheodorou, S., et al. (2015) Neurodevelopmental Outcome after a Single Course of Antenatal Steroids in Children Born Preterm: A Systematic Review and Meta-Analysis. Obstetrics &amp; Gynecology, 125, 1385-1396. &lt;br&gt;https://doi.org/10.1097/AOG.0000000000000748</mixed-citation></ref><ref id="hanspub.39346-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Amiya, R.M., Mlunde, L.B., Ota, E., et al. (2016) Antenatal Corticosteroids for Reducing Adverse Maternal and Child Outcomes in Special Populations of Women at Risk of Imminent Preterm Birth: A Systematic Review and Meta-Analysis. PLoS ONE, 11, e0147604. &lt;br&gt;https://doi.org/10.1371/journal.pone.0147604</mixed-citation></ref><ref id="hanspub.39346-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">刘慧, 谢集健, 张玮. 产前肌注糖皮质激素对早产小于胎龄儿病死率和主要并发症的影响[J]. 临床和实验医学杂志, 2018, 17(15): 1676-1679.</mixed-citation></ref><ref id="hanspub.39346-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">超未成熟儿与超低出生体重儿产前糖皮质激素使用情况及其对预后影响的多中心调查[J]. 中华围产医学杂志, 2020, 23(5): 302-310.</mixed-citation></ref><ref id="hanspub.39346-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Committee on Obstetric Practice (2017) Committee Opinion No. 713: Antenatal Corticosteroid Therapy for Fetal Maturation. Obstetrics &amp; Gynecology, 130, e102-e109. &lt;br&gt;https://doi.org/10.1097/AOG.0000000000002237</mixed-citation></ref><ref id="hanspub.39346-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">茹喜芳, 冯琪. 新生儿呼吸窘迫综合征的防治——欧洲共识指南2019版[J]. 中华新生儿科杂志(中英文), 2019, 34(3): 239-240.</mixed-citation></ref><ref id="hanspub.39346-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Hossain, S., Shah, P.S., Ye, X.Y., et al. (2016) Outborns or Inborns: Where Are the Differences? A Comparison Study of Very Preterm Neonatal Intensive Care Unit Infants Cared for in Australia and New Zealand and in Canada. Neonatology, 109, 76-84. &lt;br&gt;https://doi.org/10.1159/000441272</mixed-citation></ref></ref-list></back></article>